{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:17:08Z","timestamp":1783199828536,"version":"3.54.6"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2024-079"],"award-info":[{"award-number":["2024-079"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301759"],"award-info":[{"award-number":["82301759"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neuropharm.2026.111047","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:00:42Z","timestamp":1779980442000},"page":"111047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rosiglitazone alleviates Parkinson's disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway"],"prefix":"10.1016","volume":"297","author":[{"given":"Yubing","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahleong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4051-7368","authenticated-orcid":false,"given":"Mingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111047_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-00698-9","article-title":"Experimental and computational insights into the therapeutic mechanisms of resveratrol in a Drosophila \u03b1-synuclein model of Parkinson's disease","volume":"15","author":"Abolaji","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2026.111047_bib2","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1007\/s10787-025-01873-0","article-title":"Antidiabetic drugs in Parkinson's disease: a comprehensive meta-analysis on efficacy and safety with trial sequential analysis and GRADE evaluation","volume":"33","author":"Abou Elezz","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111047_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41586-025-09541-7","article-title":"Ribonucleotide incorporation into mitochondrial DNA drives inflammation","volume":"647","author":"Bahat","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111047_bib4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2165\/00003495-199957060-00007","article-title":"Rosiglitazone","volume":"57","author":"Balfour","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2026.111047_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fphar.2020.00268","article-title":"Rosiglitazone protects endothelial cells from irradiation-induced mitochondrial dysfunction","volume":"11","author":"Baselet","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib6","article-title":"Modeling parkinson's disease in Primates","volume":"15","author":"Bezard","year":"2025","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2026.111047_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1155175","article-title":"AGE-RAGE axis culminates into multiple pathogenic processes: a central road to neurodegeneration","volume":"16","author":"Bhattacharya","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib8","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2026.111047_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson's disease","volume":"32","author":"Brakedal","year":"2017","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2026.111047_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-\u03b3 levels in microglia and inhibits TNF-\u03b1 production: new evidences on neuroprotection in a progressive Parkinson's disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111047_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.31083\/j.jin2205132","article-title":"Pain in parkinson's disease: pathophysiology, classification and treatment","volume":"22","author":"Cattaneo","year":"2023","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40035-025-00467-8","article-title":"Parkinson's disease and glucose metabolism impairment","volume":"14","author":"Chen","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuropharm.2026.111047_bib13","article-title":"Sample preparation for rapid lipid analysis in Drosophila brain using matrix-assisted laser desorption\/ionization mass spectrometry imaging","author":"Chen","year":"2022","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuropharm.2026.111047_bib14","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/ijms21072464","article-title":"Historical perspective: models of parkinson's disease","volume":"21","author":"Chia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3390\/ijms26052093","article-title":"LRRK2 in Drosophila Melanogaster model: insights into cellular dysfunction and neuroinflammation in parkinson's disease","volume":"26","author":"Ciampelli","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s11064-014-1377-0","article-title":"PPAR\u03b3 and PGC-1\u03b1 as therapeutic targets in Parkinson's","volume":"40","author":"Corona","year":"2015","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2026.111047_bib17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41419-024-06737-z","article-title":"Seipin deficiency-induced lipid dysregulation leads to hypomyelination-associated cognitive deficits via compromising oligodendrocyte precursor cell differentiation","volume":"15","author":"Cui","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2026.111047_bib18","first-page":"32","article-title":"Unraveling the ties: type 2 diabetes and Parkinson's disease - a nano-based targeted drug delivery approach","volume":"21","author":"De","year":"2025","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.neuropharm.2026.111047_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2161-0460.1000421","article-title":"The receptor for advanced glycation endproducts (RAGE) and mediation of inflammatory neurodegeneration","volume":"8","author":"Derk","year":"2018","journal-title":"J. Alzheimers Dis. Parkinsonism"},{"key":"10.1016\/j.neuropharm.2026.111047_bib20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11571-025-10294-2","article-title":"Application of deep learning for multi-scale behavioral analysis in SNCA E46K Parkinson's disease drosophila","volume":"19","author":"Dong","year":"2025","journal-title":"Cogn. Neurodyn."},{"key":"10.1016\/j.neuropharm.2026.111047_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40035-023-00368-8","article-title":"Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions","volume":"12","author":"Dovonou","year":"2023","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.neuropharm.2026.111047_bib22","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.exger.2005.02.005","article-title":"Rapid iterative negative geotaxis (RING): a new method for assessing age-related locomotor decline in Drosophila","volume":"40","author":"Gargano","year":"2005","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108226","article-title":"Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics","volume":"156","author":"Ghannam","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuropharm.2026.111047_bib24","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.3390\/ijms26115032","article-title":"Drosophila: a versatile model in biology and medicine","volume":"26","author":"Giansanti","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168750","article-title":"Structural basis of bifunctional CTP\/dCTP synthase","volume":"436","author":"Guo","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib26","article-title":"Modulation of PM20D1 expression by rosiglitazone confers neuroprotection in tramadol-induced Parkinsonian rats","volume":"15","author":"Hadi","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.neuropharm.2026.111047_bib27","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMcibr1012075","article-title":"Rosiglitazone, PPAR\u03b3, and Type 2 diabetes","volume":"363","author":"Kahn","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2026.111047_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262211077","article-title":"Algae-derived C-Phycocyanin mitigates AGE-RAGE-Induced ER stress and mitochondrial apoptosis: implications for diabetes-associated neurodegeneration","volume":"26","author":"Lai","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1194\/jlr.M091173","article-title":"Rosiglitazone remodels the lipid droplet and britens human visceral and subcutaneous adipocytes ex vivo","volume":"60","author":"Lee","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuropharm.2026.111047_bib30","doi-asserted-by":"crossref","DOI":"10.7555\/JBR.39.20250499","article-title":"Potential crosstalk between Parkinson's disease and glucose metabolism","author":"Li","year":"2026","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.neuropharm.2026.111047_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2024.110969","article-title":"Dl-3-n-butylphthalide promotes microglial phagocytosis and inhibits microglial inflammation via regulating AGE-RAGE pathway in APP\/PS1 mice","volume":"212","author":"Lu","year":"2024","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2026.111047_bib34","article-title":"Flight and climbing assay for assessing motor functions in <em>Drosophila<\/em>","volume":"8","author":"Manjila","year":"2018","journal-title":"Bio-Protoc"},{"key":"10.1016\/j.neuropharm.2026.111047_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.expneurol.2012.02.017","article-title":"Pharmacological manipulation of peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) reveals a role for anti-oxidant protection in a model of Parkinson's disease","volume":"235","author":"Martin","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.neuropharm.2026.111047_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1055\/a-2004-3591","article-title":"Clinical manifestation of AGE-RAGE axis in neurodegenerative and cognitive impairment disorders","volume":"73","author":"Naz","year":"2023","journal-title":"Drug Res."},{"key":"10.1016\/j.neuropharm.2026.111047_bib38","doi-asserted-by":"crossref","first-page":"14311","DOI":"10.1523\/JNEUROSCI.0499-12.2012","article-title":"AMP kinase activation mitigates dopaminergic dysfunction and mitochondrial abnormalities in drosophila models of Parkinson's disease","volume":"32","author":"Ng","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40478-016-0346-z","article-title":"The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain","volume":"4","author":"Normando","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.neuropharm.2026.111047_bib40","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1007\/s10072-025-08370-w","article-title":"Metformin as a potential neuroprotective agent that influence Parkinson's disease","volume":"46","author":"Pal","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/neurosci6030089","article-title":"From fork to brain: the role of AGE-RAGE signaling and the Western diet in neurodegenerative disease","volume":"6","author":"Pomroy","year":"2025","journal-title":"NeuroScience"},{"key":"10.1016\/j.neuropharm.2026.111047_bib42","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1073\/pnas.1905028116","article-title":"Cardiac myosin activation with 2-deoxy-ATP via increased electrostatic interactions with actin","volume":"116","author":"Powers","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115266","article-title":"Oligodendrocytes drive neuroinflammation and neurodegeneration in Parkinson's disease via the prosaposin-GPR37-IL-6 axis","volume":"44","author":"Ma","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2026.111047_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107132","article-title":"Anti-diabetic drug use and reduced risk of Parkinson's disease: a community-based cohort study","volume":"128","author":"Rozani","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.neuropharm.2026.111047_bib44","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2478\/s11658-014-0205-5","article-title":"The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach","volume":"19","author":"Salahuddin","year":"2014","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.neuropharm.2026.111047_bib45","first-page":"5591","article-title":"The development of maillard reaction, and advanced glycation end product (AGE)-Receptor for AGE (RAGE) signaling inhibitors as novel therapeutic strategies for patients with AGE-related diseases","volume":"25","author":"Shen","year":"2020","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.neuropharm.2026.111047_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cells10020407","article-title":"Invertebrate models untangle the mechanism of neurodegeneration in Parkinson's disease","volume":"10","author":"Surguchov","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2026.111047_bib46","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/biom13121801","article-title":"Using selective enzymes to measure noncanonical DNA building blocks: dUTP, 5-Methyl-dCTP, and 5-Hydroxymethyl-dCTP","volume":"13","author":"Sur\u00e1nyi","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2026.111047_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1474-4422(25)00033-X","article-title":"Advances in diagnosis, classification, and management of pain in Parkinson's disease","volume":"24","author":"Tinazzi","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tips.2023.11.004","article-title":"PPAR agonists for the treatment of neuroinflammatory diseases","volume":"45","author":"Titus","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106505","article-title":"Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: current advancements and future prospects","volume":"196","author":"Tong","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.111047_bib51","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/mdc3.14063","article-title":"The quality in quality of life in Parkinson's disease: a qualitative meta-synthesis","volume":"11","author":"van Munster","year":"2024","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2026.111047_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102429","article-title":"Pivotal role of AGE-RAGE axis in brain aging with current interventions","volume":"100","author":"Vitorakis","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2026.111047_bib53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2024.12.003","article-title":"Pathogenesis of Parkinson's disease","volume":"43","author":"Xiao","year":"2025","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.neuropharm.2026.111047_bib54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00415-025-13030-2","article-title":"Global trends and projections of Parkinson's disease incidence: a 30-year analysis using GBD 2021 data","volume":"272","author":"Xu","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111047_bib55","article-title":"Mitochondrial dysfunction: mechanisms and advances in therapy","volume":"9","author":"Y","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.neuropharm.2026.111047_bib33","first-page":"239","article-title":"Aging, cellular senescence and Parkinson's disease","volume":"15","author":"Ma","year":"2025","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.neuropharm.2026.111047_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106194","article-title":"Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression","volume":"26","author":"Yu","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.neuropharm.2026.111047_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41593-024-01866-2","article-title":"Propagation of pathologic \u03b1-synuclein from kidney to brain may contribute to Parkinson's disease","volume":"28","author":"Yuan","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111047_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2025.167953","article-title":"The interplay between lipid droplets and Parkinson's disease","volume":"1871","author":"Zhao","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2026.111047_bib59","article-title":"NAD+-Boosters improve Mitochondria quality control in Parkinson's disease models via mitochondrial UPR","author":"Zhou","year":"2025","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"10.1016\/j.neuropharm.2026.111047_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41589-024-01689-z","article-title":"Phospholipid biosynthesis modulates nucleotide metabolism and reductive capacity","volume":"21","author":"Zhu","year":"2025","journal-title":"Nat. Chem. Biol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:00:07Z","timestamp":1783198807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":60,"alternative-id":["S0028390826002212"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111047","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rosiglitazone alleviates Parkinson's disease phenotypes of Drosophila via dCTP-mediated inhibition of AGE-RAGE pathway","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111047"}}